Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.02
-0.02-0.66%
At close: -
$2.97
-0.05-1.66%
After Hours: 7:58 PM EDT
Comments
Loading...
Jasper Therapeutics Analyst Ratings and Price Targets | NASDAQ:JSPR | Benzinga
Jasper Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Jasper Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
BMO Capital
JMP Securities
Evercore ISI Group
HC Wainwright & Co.
BTIG
1calculated from analyst ratings
Analyst Ratings for Jasper Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/08/2025 | Buy Now | — | BMO Capital | Kostas Biliouris35% | $15 → $4 | Downgrade | Outperform → Market Perform | Get Alert |
| 07/08/2025 | Buy Now | — | JMP Securities | Silvan Tuerkcan51% | $70 → $12 | Maintains | Market Outperform | Get Alert |
| 07/08/2025 | Buy Now | — | Evercore ISI Group | Gavin Clark-Gartner43% | $50 → $20 | Maintains | Outperform | Get Alert |
| 07/07/2025 | Buy Now | — | William Blair | Matt Phipps23% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 07/07/2025 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar39% | $40 → $20 | Maintains | Buy | Get Alert |
| 07/07/2025 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos42% | — | Downgrade | Overweight → Neutral | Get Alert |
| 07/07/2025 | Buy Now | — | BTIG | Justin Zelin45% | $64 → $20 | Maintains | Buy | Get Alert |
| 05/15/2025 | Buy Now | — | Oppenheimer | Jay Olson43% | $80 → $65 | Maintains | Outperform | Get Alert |
| 05/13/2025 | Buy Now | — | UBS | Trung Huynh43% | $38 → $33 | Maintains | Buy | Get Alert |
| 03/11/2025 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar39% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | — | UBS | Trung Huynh43% | → $38 | Initiates | → Buy | Get Alert |
| 01/10/2025 | Buy Now | — | JMP Securities | Silvan Tuerkcan51% | $70 → $70 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/10/2025 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar39% | $60 → $40 | Maintains | Buy | Get Alert |
| 01/09/2025 | Buy Now | — | RBC Capital | Gregory Renza51% | $68 → $48 | Maintains | Outperform | Get Alert |
| 01/06/2025 | Buy Now | — | JMP Securities | Silvan Tuerkcan51% | $70 → $70 | Maintains | Market Outperform | Get Alert |
| 12/23/2024 | Buy Now | — | RBC Capital | Gregory Renza51% | $68 → $68 | Reiterates | Outperform → Outperform | Get Alert |
| 12/06/2024 | Buy Now | — | BMO Capital | Etzer Darout49% | → $63 | Initiates | → Outperform | Get Alert |
| 10/24/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar39% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 10/15/2024 | Buy Now | — | JMP Securities | Silvan Tuerkcan51% | $70 → $70 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 10/15/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar39% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 09/27/2024 | Buy Now | — | JMP Securities | Silvan Tuerkcan51% | $70 → $70 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer57% | — | Reiterates | → Overweight | Get Alert |
| 09/09/2024 | Buy Now | — | JMP Securities | Silvan Tuerkcan51% | → $70 | Initiates | → Market Outperform | Get Alert |
| 08/26/2024 | Buy Now | — | Evercore ISI Group | Gavin Clark-Gartner43% | $65 → $65 | Maintains | Outperform | Get Alert |
| 08/14/2024 | Buy Now | — | RBC Capital | Gregory Renza51% | $70 → $68 | Maintains | Outperform | Get Alert |
| 08/13/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar39% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 08/05/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar39% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 07/08/2024 | Buy Now | — | BTIG | Justin Zelin45% | → $90 | Initiates | → Buy | Get Alert |
| 06/27/2024 | Buy Now | — | Stifel | Ben Burnett9% | → $86 | Initiates | → Buy | Get Alert |
| 06/18/2024 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos42% | — | Reiterates | → Overweight | Get Alert |
| 05/20/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar39% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar39% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 05/06/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar39% | → $65 | Initiates | → Buy | Get Alert |
| 04/03/2024 | Buy Now | — | Evercore ISI Group | Gavin Clark-Gartner43% | → $65 | Initiates | → Outperform | Get Alert |
| 03/28/2024 | Buy Now | — | RBC Capital | Gregory Renza51% | → $70 | Initiates | → Outperform | Get Alert |
| 03/18/2024 | Buy Now | — | TD Cowen | Yaron Werber36% | — | Initiates | → Outperform | Get Alert |
| 03/07/2024 | Buy Now | — | Oppenheimer | Jay Olson43% | $80 → $80 | Maintains | Outperform | Get Alert |
| 10/12/2023 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos42% | → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 08/14/2023 | Buy Now | — | Credit Suisse | Judah Frommer65% | → $4 | Reiterates | Outperform → Outperform | Get Alert |
| 08/11/2023 | Buy Now | — | Capital One | Tim Chiang37% | → $7 | Initiates | → Overweight | Get Alert |
| 06/12/2023 | Buy Now | — | EF Hutton | Michael King43% | → $6.85 | Reiterates | Buy → Buy | Get Alert |
| 05/25/2023 | Buy Now | — | EF Hutton | Michael King43% | → $6.85 | Assumes | → Buy | Get Alert |
| 05/16/2023 | Buy Now | — | Oppenheimer | Jay Olson43% | → $8 | Reinstates | Outperform → Outperform | Get Alert |
| 05/15/2023 | Buy Now | — | EF Hutton | Michael King43% | → $6.85 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | — | Credit Suisse | Judah Frommer65% | → $4 | Reiterates | Outperform → Outperform | Get Alert |
| 03/09/2023 | Buy Now | — | EF Hutton | Michael King43% | → $6.85 | Reiterates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos42% | → $6 | Reiterates | → Overweight | Get Alert |
| 03/09/2023 | Buy Now | — | Credit Suisse | Judah Frommer65% | → $4 | Reiterates | → Outperform | Get Alert |
| 02/27/2023 | Buy Now | — | EF Hutton | Michael King43% | → $6.85 | Reiterates | → Buy | Get Alert |
| 02/21/2023 | Buy Now | — | EF Hutton | Michael King43% | → $6.85 | Reiterates | → Buy | Get Alert |
| 02/17/2023 | Buy Now | — | EF Hutton | Michael King43% | → $6.85 | Reiterates | → Buy | Get Alert |
| 02/16/2023 | Buy Now | — | EF Hutton | Michael King43% | $4 → $6.85 | Maintains | Buy | Get Alert |
| 02/07/2023 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos42% | $10 → $6 | Reiterates | → Overweight | Get Alert |
| 01/11/2023 | Buy Now | — | Credit Suisse | Judah Frommer65% | $7 → $3 | Maintains | Outperform | Get Alert |
| 01/11/2023 | Buy Now | — | EF Hutton | Michael King43% | → $4 | Maintains | Buy | Get Alert |
| 11/14/2022 | Buy Now | — | Oppenheimer | Jay Olson43% | $21 → $8 | Maintains | Outperform | Get Alert |
| 11/01/2022 | Buy Now | — | EF Hutton | Michael King43% | → $4 | Initiates | → Buy | Get Alert |
| 07/13/2022 | Buy Now | — | Credit Suisse | Judah Frommer65% | $9 → $8 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Jasper Therapeutics (JSPR) stock?
The latest price target for Jasper Therapeutics (NASDAQ:JSPR) was reported by BMO Capital on July 8, 2025. The analyst firm set a price target for $4.00 expecting JSPR to rise to within 12 months (a possible 34.68% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Jasper Therapeutics (JSPR)?
The latest analyst rating for Jasper Therapeutics (NASDAQ:JSPR) was provided by BMO Capital, and Jasper Therapeutics downgraded their market perform rating.
When was the last upgrade for Jasper Therapeutics (JSPR)?
There is no last upgrade for Jasper Therapeutics
When was the last downgrade for Jasper Therapeutics (JSPR)?
The last downgrade for Jasper Therapeutics Inc happened on July 8, 2025 when BMO Capital changed their price target from $15 to $4 for Jasper Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Jasper Therapeutics (JSPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jasper Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jasper Therapeutics was filed on July 8, 2025 so you should expect the next rating to be made available sometime around July 8, 2026.
Is the Analyst Rating Jasper Therapeutics (JSPR) correct?
While ratings are subjective and will change, the latest Jasper Therapeutics (JSPR) rating was a downgraded with a price target of $15.00 to $4.00. The current price Jasper Therapeutics (JSPR) is trading at is $2.97, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
